Helicobacter pylori. Objectives. Upper Gastrointestinal Bleeding Peptic Ulcer Disease

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Helicobacter pylori. Objectives. Upper Gastrointestinal Bleeding Peptic Ulcer Disease"

Transcription

1 Upper Gastrointestinal Bleeding Peptic Ulcer Disease Pharmacotherapy Issues in Acute Management and Secondary Prevention Peter J. Zed, B.Sc., B.Sc.(Pharm), Pharm.D. Pharmacotherapeutic Specialist - Emergency Medicine CSU Pharmaceutical Sciences, Vancouver General Hospital Clinical Assistant Professor, Faculty of Pharmaceutical Sciences, UBC Associate Member, Department of, Faculty of Medicine, UBC Objectives To discuss the acute management of upper GI bleeding peptic ulcers with a focus on antisecretory therapy. To discuss secondary prevention strategies following acute stabilization of acute GI bleeding peptic ulcers. Epidemiology Economic Implications Marshall et al. (Am J Gastroenterol 1999;94:1841-6) ~15, admissions annually in Canada Age (yrs) Total Cost LOS (days) 55% caused by peptic ulcer disease Helicobacter pylori ASA/NSAIDS/COX-2 Inhibitors $183 $ % will stop spontaneously 6-74 $ % mortality rate.6% if <6 years of age and no co-morbidity 15% if >6 years of age and/or co-morbidity Mean (n=116) $5364 $ Helicobacter pylori NSAID-Induced Peptic Ulcer Disease 15-3% of all PUD is NSAID-induced NSAID use increases risk of PUD 3-5X 6% of NSAID users experience heartburn, pain, dyspepsia symptoms >4 weeks have increased risk of gastric ulceration 66% of all NSAID users will have endoscopic evidence of gastric lesions but clinical ulcers is 2-4% annually

2 Risk Factors for NSAID-Induced Gastropathy Wolfe et al. (NEJM 1999;32: ) Definite: Age Prior history of ulcer Duration of NSAID therapy Concomitant corticosteroid therapy Concomitant warfarin therapy Concomitant ASA/NSAID NSAID dose Serious systemic illness (CHF, RA, CAD, others) Possible: Concomitant H. pylori infection? Smoking Alcohol Acute Gastrointestinal Bleeding Peptic Ulcer Prognostic Factors: Clinical Barkun et al. (Aliment Pharmacol Ther 1999;13: ) hemodynamic instability hematochezia from upper GI source >6 years of age units of transfused blood concurrent illness onset of bleeding while hospitalized coagulopathy Prognostic Factors: Endoscopic Barkun et al. (Aliment Pharmacol Ther 1999;13: ) High Risk Bleeds 6 55% % 43% Spurting Vessel 2 1 5% 1% Clean Base Flat Spot Clot NBVV Active Bleed Non-Bleeding Visible Vessel Overlying Clot Prevalence

3 Time to Goals of Therapy Hemodynamic Stabilization and Resuscitation (ABC) Determine Cause Stop Bleeding Prevent Recurrence <24h 24-48h 48-72h 72-96h h >168h Management Endoscopic Therapy: Meta-Analysis Cook et al. Gastroenterol 1992;12: Oxygen Fluid Blood Transfusion Endoscopic Therapy Pharmacotherapy Endpoint Death OR (95% CI).38 ( ).36 ( ).55 (.4-.76) Endoscopy Better 1 ODDS RATIO No Endoscopy Better Pharmacological Therapy Role of Gastric Acid on Hemostasis Splanchnic blood pressure modifiers vasopressin, octreotide, somatostatin Antifibrinolytic Agents tranexamic acid Antisecretory Agents H2-receptor antagonists (H2RA) proton-pump inhibitors (PPI) Impairs clot formation impairs platelet aggregation and causes disaggregation Accelerates clot lysis acid-stimulated pepsin Impairs mucous/bicarbonate barrier Aliment Pharmacol Ther 1999;16:

4 H2RA in Acute GI Bleeding: Meta-Analysis Collins et al. (NEJM 1985;313:66-6) Famotidine in Acute GI Bleeding Walt et al. (Lancet 1992;34:158-62) 27 trials, N=25 randomized, placebocontrolled trials H2RA vs % Acute Endoscopically-proven GI Bleeding Peptic Ulcer P, MC, R, DB, PC n=15 RRR -2 ENDPOINTS -25 rebleeding -3 surgery -35 mortality -4 22% 3%* *p=.2 Mortality Famotidine 1 mg IV bolus followed by 3.2 mg/h x 72h Primary: Death during hospitalization Secondary: Famotidine in Acute GI Bleeding Walt et al. (Lancet 1992;34:158-62) Tolerance: Intragastric ph>4 Merki and Wilder-Smith (Gastroenterol 1994;16:6-4) % 23.9% p=ns for all endpoints %* 67% 96%* % 5.% 15.5% 17.1% % Death Famotidine 1 Day 1 Day 3 *p<.1 Tolerance: Daily Dose Merki and Wilder-Smith (Gastroenterol 1994;16:6-4) Proton-Pump Inhibitors Mechanism of Action mg mg Histamine Receptor mg camp Protein Kinase Ca 2+ Calmodulin Muscarinic Receptor Ca mg K + K + Cl - Gastrin Receptor ATPase Day 1 Day 3 48 Day 1 Day 3 H + Cl - K +

5 PPI is Acute GI Bleeding Peptic Ulcers 12 randomized, controlled trials since 199 omeprazole only PPI evaluated in these trials 5 placebo-controlled, 7 H2RA-controlled Issues Efficacy? Safety? Cost? PPI Alone vs. Adjuvant to Endoscopy? PPI Alone vs. Endoscopy Alone? Intermittent Dosing vs. Continuous Infusion? IV vs. PO? : Intermittent Bolus Daneshmend et al. (BMJ 1992;34:143-7) Clinically-Diagnosed Acute GI Bleeding P, MC, R, DB, PC n= mg IV bolus followed by 4 mg IV Q8h x 24h followed by 4 mg PO BID x 3 days Primary: Death Transfusion : Intermittent Bolus Daneshmend et al. (BMJ 1992;34:143-7) %* 15% 11%* 11% *p=ns 6.9% 5.3%* Mortality 8 mg IV bolus then 4 mg IV Q8h x 24h then 4 mg PO BID x 3 days Proven Gastric/Duodenal Ulcer Daneshmend et al. (BMJ 1992;34:143-7) % 23.6% N= % 18.3% 5.1% 9.3% Mortality 8 mg IV bolus then 4 mg IV Q8h x 24h then 4 mg PO BID x 3 days : Intermittent Bolus/Endoscopy Villanueva et al. (Endoscopy 1995;27:38-12) : Intermittent Bolus/Endoscopy Villanueva et al. (Endoscopy 1995;27:38-12) Acute Endoscopically-proven Actively Bleeding Peptic Ulcer P, R, OL n=86 8 mg IV bolus followed by 4 mg IV Q8h x 4 days followed by 2 mg PO daily 5 mg IV Q6h x 24h followed by 15 mg PO BID % 24% 2% 22% p=ns for all endpoints 7% All patients received endoscopic therapy within 4h 5 2% Primary: Death Death 8 mg IV bolus then 4 mg IV Q8h x 4 days then 2 mg/day 5 mg IV Q6h x 24h then 15 mg PO BID

6 Summary: Intermittent Bolus Study PPI Control Result Brunner (199) Daneshmend (1992) Lanas (1995) Villanueva (1995) Grosso (1995) TOTAL (n=19) (n=578) (n=23) (n=45) (n=21) N=686 (n=2) (n=569) (n=23) (n=41) Endo/Ran (n=21) Control N=674 Bleeding No Difference No Difference No Difference : Continuous Infusion/Endoscopy Schaffalitzky et al. (Scand J Gastroenterol 1997;32:32-7) Acute Endoscopically-proven Actively Bleeding Peptic Ulcer P, MC, R, DB, PC n=265 8 mg IV bolus followed by 8 mg/h x 3 days Overall Outcome (ordinal scale) Primary Variables: Death (5) (4) Endoscopic Treatment (3) Transfusion > 3 units (2) Transfusion 1-3 units (1) All patients received endoscopic therapy within 12h : Continuous Infusion/Endoscopy Schaffalitzky et al. (Scand J Gastroenterol 1997;32:32-7) : Continuous Infusion/Endoscopy Schaffalitzky et al. (Scand J Gastroenterol 1997;32:32-7) Overall Outcome of Treatment after 72 hours Category Outcome * (n=13) (n=135) 5 Death Endoscopy > 3 units units *p=.4 p=nr 1 91% % p= % p= % 2 5.4% 11.1% 1 Bleeding Treatment Success 8 mg IV bolus then 8 mg/h x 72 hours : Continuous Infusion Hasselgren et al. (Scand J Gastroenterol 1997;32:328-33) Acute Endoscopically-proven Actively Bleeding Peptic Ulcer P, MC, R, DB, PC n=322 8 mg IV bolus followed by 8 mg/h x 3 days Overall Outcome (ordinal scale) Primary Variables: Death (5) (4) Endoscopic Treatment (3) Transfusion > 3 units (2) Transfusion -3 units (1) Secondary Variables: Degree of bleeding Duration of bleeding Endoscopic Treatment Mortality Treatment Failure : Continuous Infusion Hasselgren et al. (Scand J Gastroenterol 1997;32:328-33) p=.4 p=.3 p= % 18.1% % 1 8.2% 8 6.2% % 2.6%.6% Death Treatment Failure 8 mg IV bolus then 8 mg/h x 72 hours

7 : Continuous Infusion/Endoscopy Lau et al. (NEJM 2;343:31-6) Acute Endoscopically-proven Actively Bleeding Peptic Ulcer P, R, DB, PC n=24 8 mg IV bolus followed by 8 mg/h x 3 days followed by 2 mg PO daily x 8 wks x 3 days followed by omeprazole 2 mg PO daily x 8 wks All patients received endoscopic therapy within 24h Primary: Secondary: at 3 days at 3 days Death at 3 days : Continuous Infusion/Endoscopy Lau et al. (NEJM 2;343:31-6) Summary: Continuous Infusion % % 4.2% Day 3 Day 7 Day % ARR = 15.8% NNT = 7 p<.1 6.7% Study PPI Control Result Hasselgren (1997) Schaffalitzky (1997) Lin (1998) Lau (2) TOTAL (n=159) (n=13) (n=5) (n=12) N=459 (n=163) (n=135) (n=5) (n=12) Control N=468 Overall Outcome Overall Outcome Meta-Analysis Zed PJ et al. (Ann Pharmacother 21;35: ) Meta-Analysis Zed PJ et al. (Ann Pharmacother 21;35: ) Daneshmend Lanas Villanueva Grosso Hasselgren Schaffalitsky Lin Khuroo Lau TOTAL Rebleed OR.5, (95% CI ) p=.2; NNT = 9 Daneshmend Lanas Villanueva Grosso Hasselgren Schaffalitsky Lin Khuroo Lau TOTAL OR.47, (95% CI ) p=.3; NNT = 17 PPI Better 1 H2RA/ Better PPI Better 1 H2RA/ Better ODDS RATIO ODDS RATIO

8 vs. /Endoscopy Sung et al. (Ann Intern Med 23;139:237-43) vs. /Endoscopy Sung et al. (Ann Intern Med 23;139:237-43) Acute Endoscopically-proven High Risk Peptic Ulcer NBVV/Adherent Clot P, R, SB, PC n= % p=.9 Endoscopy Sham Endoscopy 8 6 All patients omeprazole 8 IV bolus then 8 mg/h x 72h % Primary: at 3 days at 3 days Secondary: at 3 days Death at 3 days /Endoscopy : Oral Dosing Khuroo et al. (NEJM 1997;336:154-8) : Oral Dosing Khuroo et al. (N Engl J Med 1997;336:154-8) Acute Endoscopically-proven GI Bleeding Peptic Ulcer P, R, DB, PC n=22 4 mg PO BID x 5 days Primary: Death Transfusion p<.1 7.9% p< % p< % 23.6% p=ns 1.9% 7.3% 1.8% 5.5% Death Transfusion 4 mg PO BID x 5 days : Oral Dosing Javid et al. (Am J Med 21;111:28-4.) : Oral Dosing Javid et al. (Am J Med 21;111:28-4.) Acute Endoscopically-proven GI Bleeding Peptic Ulcer P, R, DB, PC n=166 4 mg PO BID x 5 days Primary: Transfusion All patients received endoscopic therapy within 24h p<.1 73% p<.2 p=ns p=ns 35% 21% 7% 9% 2% 1% 2% Death Transfusion 4 mg PO BID x 5 days

9 Conclusions H2RA have no role in the management of AGIB cannot provide necessary ph increase tolerance develops quickly no benefit in clinical trials PPI beneficial in select patient populations maintains desired intragastric ph tolerance has not been reported Conclusions Helicobacter pylori Intermittent Dosing of PPI minimal benefit Continuous Infusion PPI offers most promising results endoscopically-proven high-risk bleeding peptic ulcer reduced rebleeding and need for surgery no reduction in mortality pantoprazole 8 mg IV bolus followed by 8 mg/h x 72 hours Future Research IV vs. PO? Role of pre-endoscopy PPI H.pylori & Duodenal Ulcer Recurrence O Brien et al. (Arch Intern Med 1995;155: ) Prevention of Recurrence: H.pylori Eradication Endoscopic recurrence at 6 months (%) Eradicate Study Cure Rate Control H. pylori Tx Graham (1993) 76% 29% % Labenz (1994) 1% 38% % Rokkas (1995) 81% 33% % Jaspersen (1995) 83% 27% % Santander (1995) 79% 12% 2% Maier (1995) 9% 12% % Mekel & DenBoer Gough Becker Hansky & Korman Lauritsen Paoluzi Fitzpatrick Korman Dronfield Bardhand Blackwood Gray

10 H.pylori Eradication Can J Gastroenterol 1998;12:31-41 Prevention: Misoprostol (MUCOSA) Silverstein et al. (Ann Intern Med 1995;123:241-9) FIRST LINE PPI PO BID* Metronidazole 5 mg PO BID Clarithromycin 25 mg PO BID PPI-MC 25 PPI PO BID* Metronidazole 5 mg PO BID Clarithromycin 5 mg PO BID PPI-MC 5 PPI PO BID* Amoxicillin 1 mg PO BID Clarithromycin 5 mg PO BID PPI-AC SECOND LINE PPI PO BID* Bismuth ii tabs PO QID Metronidazole 25 mg PO QID Tetracycline 5 mg PO QID PPI-BMT 3 mg PO BID Bismuth 12 mg PO QID Metronidazole 25 mg PO QID Tetracycline 5 mg PO QID R-BMT (14 day regimen) * 2 mg or Lansoprazole 3 mg or Pantoprazole 4 mg P, MC, R, DB, PC N=8843 RA, >52 yrs, NSAID-users Misoprostol 2 mcg PO QID vs. ENDPOINT Serious GI Complications at 6 months ARR=.38% NNT=264 p=.49.57% Complications Misoprostol.95% Prevention: H2RA NSAID-Induced Peptic Ulcer Disease Treatment and Prevention of Recurrence NSAID-Induced Peptic Ulcer Disease % 11% p<.5 28% PUD Famotidine 4 mg/d Famotidine 8 mg/d Taha, NEJM 1996;334: % 5.7% Gastric Ulcer p=.9 Misoprostol 2 mcg PO QID Rantidine 15 mg PO BID Raskin, Am J Gastroenterol 1996;91:223-7 ASTRONAUT (N Engl J Med 1998;338:719-26) P, MC, R, DB, N=541 NSAID-induced PUD vs. ENDPOINTS Healing at 8 weeks Maintenance at 6 months % p<.1 NNT = 6 8% 79% Healing p<.1 NNT = 8 72% 59% Maintenance 2 mg/day 4 mg/day Treatment and Prevention of Recurrence NSAID-Induced Peptic Ulcer Disease OMNIUM 1 (N Engl J Med 1998;338:727-34) 8 P, MC, R, DB, N=935 6 NSAID-induced PUD 4 Misoprostol vs. 2 p=ns 76% 75% 71% p=.1 NNT = 8 61% 48% 27% ENDPOINTS Healing at 8 weeks Maintenance at 6 months Healing Maintenance Misoprostol 2 mg/day 4 mg/day

11 Celecoxib vs. Diclofenac/ Chan et al. (NEJM 22;347:214-1) OA/RA, H. pylori-negative endoscopically-proven healed peptic ulcer P, R, DB, PC n=287 Celecoxib 2 mg PO BID po daily x 6 months Diclofenac 75 mg PO BID 2 mg PO daily x 6 months All patients received endoscopic evaluation every 2 months x 3 Celecoxib vs. Diclofenac/ Chan et al. (NEJM 22;347:214-1) Probability of Recurrent Ulcer Bleeding 16 recurrent ulcers at 6 months Difference: -1.5% (95% CI 6.8% to 3.8%, p=ns) 6.4% 4.9% PRIMARY ENDPOINT: within 6 months clinical features/hg drop + endoscopic confirmation Celecoxib vs. Diclofenac/ Chan et al. (NEJM 22;347:214-1) Post Acute Therapy for AGIB YES Is patient Hp+? YES Treat with Hp eradication therapy NO Is patient taking NSAIDS? NO PPI X 4-8 weeks YES Reduce to lowest dose possible + PPI NO Can NSAID be discontinued? YES

Review article: management of peptic ulcer bleeding the roles of proton pump inhibitors and Helicobacter pylori eradication

Review article: management of peptic ulcer bleeding the roles of proton pump inhibitors and Helicobacter pylori eradication Aliment Pharmacol Ther 2004; 19 (Suppl. 1): 66 70. Review article: management of peptic ulcer bleeding the roles of proton pump inhibitors and Helicobacter pylori eradication G. HOLTMANN* & C. W. HOWDEN

More information

On-Call Upper GI Bleeding. Upper Gastrointestinal Bleeding

On-Call Upper GI Bleeding. Upper Gastrointestinal Bleeding On-Call Upper GI Bleeding John R Saltzman MD, FACG Director of Endoscopy Brigham and Women s Hospital Associate Professor of Medicine Harvard Medical School Upper Gastrointestinal Bleeding 300,000000 hospitalizations/year

More information

Medical and Endoscopic Management of Upper GI Bleeding

Medical and Endoscopic Management of Upper GI Bleeding Medical and Endoscopic Management of Upper GI Bleeding David A. Greenwald, MD Albert Einstein College of Medicine Montefiore Medical Center ACG Annual Meeting 2013 1 Fu K, Fujimori T. N Engl J Med 2006;354:283-283

More information

MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)

MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Routine endoscopic investigation of patients of any age, presenting with dyspepsia

More information

Simon Everett. Consultant Gastroenterologist, SJUH, Leeds. if this is what greets you in the morning, you probably need to go see a doctor

Simon Everett. Consultant Gastroenterologist, SJUH, Leeds. if this is what greets you in the morning, you probably need to go see a doctor Simon Everett Consultant Gastroenterologist, SJUH, Leeds if this is what greets you in the morning, you probably need to go see a doctor Presentation Audit data and mortality NICE guidance Risk assessment

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium esomeprazole, 40mg vial of powder for solution for intravenous injection or infusion (Nexium I.V. ) No. (578/09) AstraZeneca 09 October 2009 The Scottish Medicines Consortium

More information

CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS. 1. Which of the following is not a common cause of peptic ulcer disease (PUD)?

CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS. 1. Which of the following is not a common cause of peptic ulcer disease (PUD)? CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS 1. Which of the following is not a common cause of peptic ulcer disease (PUD)? A. Chronic alcohol ingestion B. Nonsteroidal antiinflammatory

More information

Proton Pump Inhibitors Drug Class Prior Authorization Protocol

Proton Pump Inhibitors Drug Class Prior Authorization Protocol Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review

More information

Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding (Review)

Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding (Review) Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding (Review) Sreedharan A, Martin J, Leontiadis GI, Dorward S, Howden CW, Forman D, Moayyedi P This

More information

Drug Class Monograph

Drug Class Monograph Drug Class Monograph Class: Proton Pump Inhibitors Drugs: Aciphex Sprinkle (rabeprazole), Dexilant (dexlansoprazole), Lansoprazole, Nexium (esomeprazole capsule, esomeprazole granules), Omeprazole, Pantoprazole,

More information

KK College of Nursing Peptic Ulcer Badil D ass Dass, Lecturer 25th July, 2011

KK College of Nursing Peptic Ulcer Badil D ass Dass, Lecturer 25th July, 2011 KK College of Nursing Peptic Ulcer Badil Dass, Lecturer 25 th July, 2011 Objectives: By the end of this lecture, the students t will be able to: Define peptic pp ulcer Describe the etiology and pathology

More information

Anticoagulants are a contributing factor. Other causes are Mallory-Weiss tears, AV malformations, and malignancy and aorto-enteric fistula.

Anticoagulants are a contributing factor. Other causes are Mallory-Weiss tears, AV malformations, and malignancy and aorto-enteric fistula. Upper GI Bleeding EMU2018 Dr. Walter Himmel MD Incidence: In non-cirrhotics, the commonest causes are peptic ulcer disease (50%) followed by erosive gastritis. In cirrhotic patients, variceal bleeding

More information

Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding (Review)

Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding (Review) Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding (Review) Sreedharan A, Martin J, Leontiadis GI, Dorward S, Howden CW, Forman D, Moayyedi P This

More information

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées. Proton Pump Inhibitor Project Overview: Summaries

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées. Proton Pump Inhibitor Project Overview: Summaries OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 1 March 2007 Proton Pump Inhibitor Project Overview: Summaries Supporting Informed Decisions À l appui des décisions éclairées This Executive Summary is based

More information

Non-steroidal anti-inflammatory drugs: who should receive prophylaxis?

Non-steroidal anti-inflammatory drugs: who should receive prophylaxis? Aliment Pharmacol Ther 2004; 20 (Suppl. 2): 59 64. Non-steroidal anti-inflammatory drugs: who should receive prophylaxis? C. J. HAWKEY Wolfson Digestive Diseases Centre, Institute of Clinical Research,

More information

GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA

GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA MANAGEMENT Dyspepsia refers to a spectrum of usually intermittent upper gastrointestinal symptoms, including epigastric pain and heartburn. For the majority

More information

Case 4: Peptic Ulcer Disease. Requejo, April Salandanan, Geralyn Talingting, Vennessa Tanay, Arvie

Case 4: Peptic Ulcer Disease. Requejo, April Salandanan, Geralyn Talingting, Vennessa Tanay, Arvie Case 4: Peptic Ulcer Disease Requejo, April Salandanan, Geralyn Talingting, Vennessa Tanay, Arvie Case 4: PUD Problem List: 1. Peptic Ulcer Disease SOAP Note: S Patient is complaining of abdominal pain

More information

Helicobacter pylori: Diagnosis, treatment and risks of untreated infection

Helicobacter pylori: Diagnosis, treatment and risks of untreated infection Helicobacter pylori: Diagnosis, treatment and risks of untreated infection Klaus Mönkemüller Department of Gastroenterology, Hepatology und Infectius Diseases Otto-von-Guericke University, Magdeburg bb

More information

UGI BLEED. Dr. KPP Abhilash Associate Professor Department of Emergency Medicine Christian Medical College, Vellore

UGI BLEED. Dr. KPP Abhilash Associate Professor Department of Emergency Medicine Christian Medical College, Vellore UGI BLEED Dr. KPP Abhilash Associate Professor Department of Emergency Medicine Christian Medical College, Vellore Outline UGI bleed: etiology and presentation Management: Non variceal / variceal bleed

More information

Turning off the tap: Endoscopy Blood & Guts: Transfusion and bleeding in the medical patient

Turning off the tap: Endoscopy Blood & Guts: Transfusion and bleeding in the medical patient Turning off the tap: Endoscopy Blood & Guts: Transfusion and bleeding in the medical patient John Greenaway 1 Turning off the tap: Endoscopy Answer the questions Benefits and risks of endoscopy Urgency

More information

Copy right protected Page 1

Copy right protected Page 1 DRUGS USED IN ULCERS AND GIT DISORDERS A peptic ulcer, also known as PUD or peptic ulcer disease is an ulcer of an area of the gastrointestinal tract that is usually acidic and thus extremely painful.

More information

The New England Journal of Medicine

The New England Journal of Medicine The New England Journal of Medicine Copyright, 2000, by the Massachusetts Medical Society VOLUME 343 A UGUST 3, 2000 NUMBER EFFECT OF INTRAVENOUS OMEPRAZOLE ON RECURRENT BLEEDING AFTER ENDOSCOPIC TREATMENT

More information

Pantoprazole infusion as adjuvant therapy to endoscopic treatment in patients with peptic ulcer bleeding: Prospective randomized controlled trial

Pantoprazole infusion as adjuvant therapy to endoscopic treatment in patients with peptic ulcer bleeding: Prospective randomized controlled trial Blackwell Publishing AsiaMelbourne, AustraliaJGHJournal of Gastroenterology and Hepatology0815 93192006 Blackwell Publishing Asia Pty Ltd200621716721Original Article Pantoprazole in bleeding peptic ulcerssa

More information

The PPI Doesn t Work, Now What? PPI Non-responsive Dyspepsia. Disclosures

The PPI Doesn t Work, Now What? PPI Non-responsive Dyspepsia. Disclosures The PPI Doesn t Work, Now What? PPI Non-responsive Dyspepsia Lana Bistritz MD FRCPC Royal Alexandra Hospital GI Update 2016 Disclosures I have no relevant financial disclosures I will be discussing off

More information

COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION

COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Phil J Gastroenterol 2006; 2: 25-29 COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Marianne P Collado, Ma Fatima P Calida, Peter P Sy,

More information

Sangrado Gastrointestinal Alto Upper GI Bleeding

Sangrado Gastrointestinal Alto Upper GI Bleeding Sangrado Gastrointestinal Alto Upper GI Bleeding Curso Internacional Retos Clinicos en la Gastroenterologia de Urgencias Asociacion Colombiana de Gastroenterologia 31 de Agosto, 2012 Pereira, Risaralda

More information

Stressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU

Stressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU Stressed Out: Evaluating the Need for Stress Ulcer Prophylaxis in the ICU Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds November 8, 2016 2016 MFMER slide-1 Objectives Identify the significance

More information

Intermittent vs Continuous Proton Pump Inhibitor Therapy for High-Risk Bleeding Ulcers A Systematic Review and Meta-analysis

Intermittent vs Continuous Proton Pump Inhibitor Therapy for High-Risk Bleeding Ulcers A Systematic Review and Meta-analysis Research Original Investigation Intermittent vs Continuous Proton Pump Inhibitor Therapy for High-Risk Bleeding Ulcers A Systematic Review and Meta-analysis Hamita Sachar, MD; Keta Vaidya, MD; Loren Laine,

More information

ORIGINAL INVESTIGATION

ORIGINAL INVESTIGATION ORIGINAL INVESTIGATION A Prospective Randomized Comparative Trial Showing That Prevents Rebleeding in Patients With Bleeding Peptic Ulcer After Successful Endoscopic Therapy Hwai-Jeng Lin, MD, FACG; Wen-Ching

More information

Proton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014

Proton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.09.01 Subject: Proton Pump Inhibitors Page: 1 of 7 Last Review Date: June 12, 2014 Proton Pump Inhibitors

More information

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées

COMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 6 March 2007 Gap Analysis Report for the Prescribing and Use of Proton Pump Inhibitors (PPIs) Supporting Informed Decisions À l appui des décisions éclairées

More information

Review article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors

Review article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors Aliment Pharmacol Ther 2003; 17 (Suppl. 1): 10 15. Review article: gastric acidity ) comparison of esomeprazole with other proton pump inhibitors J. G. HATLEBAKK Department of Medicine, Haukeland Sykehus,

More information

Controversies in Gastroenterology in Asia

Controversies in Gastroenterology in Asia June 13-15, 2013 Berlin, Germany Prof. Joseph Sung The Chinese University of Hong Kong Controversies in Gastroenterology in Asia Disclosure of Potential Conflict of Interest: Nothing to Disclose June 13-15,

More information

Peptic ulcers remain the most common cause of upper

Peptic ulcers remain the most common cause of upper CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:33 47 STATE OF THE ART Endoscopic Therapy for Bleeding Ulcers: An Evidence-Based Approach Based on Meta-Analyses of Randomized Controlled Trials LOREN LAINE*

More information

Proton Pump Inhibitor Treatment Decreases the Incidence of Upper Gastrointestinal Disorders in Elderly Japanese Patients Treated with NSAIDs

Proton Pump Inhibitor Treatment Decreases the Incidence of Upper Gastrointestinal Disorders in Elderly Japanese Patients Treated with NSAIDs ORIGINAL ARTICLE Proton Pump Inhibitor Treatment Decreases the Incidence of Upper Gastrointestinal Disorders in Elderly Japanese Patients Treated with NSAIDs Yuki Sakamoto, Tadashi Shimoyama, Satoru Nakagawa,

More information

Stress Ulcer Prophylaxis In The ICU. Scott W. Wolf Anesthesiology Critical Care Medicine

Stress Ulcer Prophylaxis In The ICU. Scott W. Wolf Anesthesiology Critical Care Medicine Stress Ulcer Prophylaxis In The ICU Scott W. Wolf Anesthesiology Critical Care Medicine Some history Stress Ulceration described in ICU patients as long as 45 years ago Patients had a constellation of

More information

Treating H. pylori in 2016

Treating H. pylori in 2016 Treating H. pylori in 2016 William D. Chey, MD, FACG Professor of Medicine University of Michigan The Case: A 38 yo Russian man presents with recurrent epigastric pain which occurs after meals and sometimes

More information

Acid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs Prof. Sheila Crowe

Acid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs Prof. Sheila Crowe Acid-Peptic Diseases of the Stomach and Duodenum Including Helicobacter pylori and NSAIDs 1 Division of Gastroenterology UC San Diego School of Medicine Clinical presentations of Helicobacter pylori infection

More information

PRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW

PRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW PRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY Dyspepsia refers to a broad range of symptoms related

More information

Surgery for Complications of Peptic Ulcer Disease (Definitive Treatment)

Surgery for Complications of Peptic Ulcer Disease (Definitive Treatment) Surgery for Complications of Peptic Ulcer Disease (Definitive Treatment) Amid Keshavarzi, MD UCHSC Grand Round 3/20/2006 Department of Surgery Introduction Epidemiology Pathophysiology Clinical manifestation

More information

Updates in Evaluation and Management of Dyspepsia and H. Pylori Infection

Updates in Evaluation and Management of Dyspepsia and H. Pylori Infection Updates in Evaluation and Management of Dyspepsia and H. Pylori Infection Isabel Lee, MD Associate Professor of Health Sciences UCSF Department of Family and Community Medicine Disclosures None 2 Session

More information

Helicobacter pylori Eradication Therapy Success Regarding Different Treatment Period Based on Clarithromycin or Metronidazole Triple-Therapy Regimens

Helicobacter pylori Eradication Therapy Success Regarding Different Treatment Period Based on Clarithromycin or Metronidazole Triple-Therapy Regimens Helicobacter ISSN 1523-5378 Filipec Blackwell Oxford, HEL 1083-4389 1523-5378 Journal XXX Original H. 2008 pylori Kanizaj compilation The UK Eradication Publishing Article Authors et al. Ltd 2008 Therapy

More information

Use of NSAIDs and infection with Helicobacter pylori what does the rheumatologist need to know?

Use of NSAIDs and infection with Helicobacter pylori what does the rheumatologist need to know? Rheumatology 2008;47:1342 1347 Advance Access publication 13 May 2008 doi:10.1093/rheumatology/ken123 Use of NSAIDs and infection with Helicobacter pylori what does the rheumatologist need to know? U.

More information

STRESS ULCER PROPHYLAXIS SUMMARY

STRESS ULCER PROPHYLAXIS SUMMARY DISCLAIMER: These guidelines were prepared jointly by the Surgical Critical Care and Medical Critical Care Services at Orlando Regional Medical Center. They are intended to serve as a general statement

More information

EMILOK Global. (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated

EMILOK Global. (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated EMILOK Global (omeprazole) Composition: Each capsule contains 20 mg omeprazole as enteric-coated granules. Properties: Emilok (omeprazole) belongs to the group of proton pump inhibitors, inhibits both

More information

Gastrointestinal bleeding, the most common cause of hospitalization

Gastrointestinal bleeding, the most common cause of hospitalization The new england journal of medicine Clinical Practice Caren G. Solomon, M.D., M.P.H., Editor Upper Gastrointestinal Bleeding Due to a Peptic Ulcer Loren Laine, M.D. This Journal feature begins with a case

More information

Peptic Ulcer Disease Today

Peptic Ulcer Disease Today 1 of 11 2/24/2007 2:54 PM www.medscape.com To Print: Click your browser's PRINT button. NOTE: To view the article with Web enhancements, go to: http://www.medscape.com/viewarticle/522900 Peptic Ulcer Disease

More information

Clinical Study Effect of High-Dose Oral Rabeprazole on Recurrent Bleeding after Endoscopic Treatment of Bleeding Peptic Ulcers

Clinical Study Effect of High-Dose Oral Rabeprazole on Recurrent Bleeding after Endoscopic Treatment of Bleeding Peptic Ulcers Gastroenterology Research and Practice Volume 2012, Article ID 317125, 8 pages doi:10.1155/2012/317125 Clinical Study Effect of High-Dose Oral Rabeprazole on Recurrent Bleeding after Endoscopic Treatment

More information

Prevention of Acute NSAID-Induced Gastroduodenal Damage: Which Strategy is the Best?

Prevention of Acute NSAID-Induced Gastroduodenal Damage: Which Strategy is the Best? Prevention of Acute NSAID-Induced Gastroduodenal Damage: Which Strategy is the Best? Shaden Salamae MD a, Meir Antopolsky MD a, Ruth Stalnikowicz MD a * Department of Emergency Medicine, Hadassah University

More information

New Techniques. Incidence of Peptic Ulcer. Changing. Contents - with an emphasis on peptic ulcer bleeding. Cause of death in peptic ulcer bleeding

New Techniques. Incidence of Peptic Ulcer. Changing. Contents - with an emphasis on peptic ulcer bleeding. Cause of death in peptic ulcer bleeding Contents - with an emphasis on peptic ulcer bleeding New Techniques in Treating GI Bleeding Incidence and cause of death Acid suppression Endoscopic hemostasis Prediction of rebleeding and death Second

More information

QUICK QUERIES. Topical Questions, Sound Answers

QUICK QUERIES. Topical Questions, Sound Answers QUICK QUERIES Topical Questions, Sound Answers Dyspepsia: An Evidence-Based Approach Alan B. R. Thomson, MD, PhD, FRCPC, FACP, FACG Presented at the University of Alberta s Medical Grand Rounds, University

More information

SESSION 5 2:20 3:35 PM

SESSION 5 2:20 3:35 PM SESSION 5 2:20 3:35 PM for the Primary Prevention of Cardiovascular Disease: A Personalized Approach SPEAKER Samia Mora MD, MHS Presenter Disclosure Information The following relationships exist related

More information

Cite this article as: BMJ, doi: /bmj f (published 31 January 2005)

Cite this article as: BMJ, doi: /bmj f (published 31 January 2005) Cite this article as: BMJ, doi:10.1136/bmj.38356.641134.8f (published 31 January 2005) Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding Grigoris I Leontiadis,

More information

ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use

ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use American Journal of Gastroenterology ISSN 0002-9270 C 2008 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2008.02216.x Published by Blackwell Publishing CLINICAL REVIEWS This article is copublished

More information

Omeprazole before Endoscopy in Patients with Gastrointestinal Bleeding

Omeprazole before Endoscopy in Patients with Gastrointestinal Bleeding T h e n e w e ng l a nd j o u r na l o f m e dic i n e original article before Endoscopy in Patients with Gastrointestinal Bleeding James Y. Lau, M.D., Wai K. Leung, M.D., Justin C.Y. Wu, M.D., Francis

More information

Upper gastrointestinal (GI) bleeding represents a substantial

Upper gastrointestinal (GI) bleeding represents a substantial Clinical Guidelines Consensus Recommendations for Managing Patients with Nonvariceal Upper Gastrointestinal Bleeding Alan Barkun, MD, MSc; Marc Bardou, MD, PhD; and John K. Marshall, MD, MSc, for the Nonvariceal

More information

Management of nonsteroidal anti-inflammatory drug

Management of nonsteroidal anti-inflammatory drug BYRON CRYER, MD ABSTRACT OBJECTIVE: To describe risk factors and review appropriate management strategies for patients who experience nonsteroidal anti-inflammatory drug (NSAID)-related gastrointestinal

More information

MANAGING GI BLEEDING IN A COMMUNITY HOSPITAL SETTING DR M. F. M. BRULE

MANAGING GI BLEEDING IN A COMMUNITY HOSPITAL SETTING DR M. F. M. BRULE MANAGING GI BLEEDING IN A COMMUNITY HOSPITAL SETTING DR M. F. M. BRULE DISCLOSURES Presenter: Dr Michele Brule Relationships with commercial interests: None OBJECTIVES Assess the severity of GI bleeding

More information

ICU Volume 14 - Issue 2 - Summer Matrix

ICU Volume 14 - Issue 2 - Summer Matrix ICU Volume 14 - Issue 2 - Summer 2014 - Matrix Upper Gastrointestinal Bleeding Authors David Osman, MD Medical Intensive Care Unit Paris-South University Hospitals Assistance Publique-Hôpitaux de Paris

More information

What Is Peptic Ulcer Disease?

What Is Peptic Ulcer Disease? What Is Peptic Ulcer Disease? Peptic ulcer disease is when painful sores form in the lining of the stomach, duodenum (start of the small intestine) or bowels. An ulcer can cause belly pain and, in some

More information

Peptic Ulcer Bleeding Risk. The Role of Helicobacter Pylori Infection in NSAID/Low-Dose Aspirin Users

Peptic Ulcer Bleeding Risk. The Role of Helicobacter Pylori Infection in NSAID/Low-Dose Aspirin Users 684 ORIGINAL CONTRIBUTIONS nature publishing group see related editorial on page x Peptic Ulcer Bleeding Risk. The Role of Helicobacter Pylori Infection in NSAID/Low-Dose Aspirin Users C. Sostres, MD 1,

More information

Bleeding Prevention in an Era of Expanding Combination Antithrombotic Therapies

Bleeding Prevention in an Era of Expanding Combination Antithrombotic Therapies Bleeding Prevention in an Era of Expanding Combination Antithrombotic Therapies Muthiah Vaduganathan, MD MPH Cardiovascular Medicine Brigham and Women s Hospital December 8 th, 2017 Disclosures None Key

More information

Helicobacter Pylori Testing HELICOBACTER PYLORI TESTING HS-131. Policy Number: HS-131. Original Effective Date: 9/17/2009

Helicobacter Pylori Testing HELICOBACTER PYLORI TESTING HS-131. Policy Number: HS-131. Original Effective Date: 9/17/2009 Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,

More information

NSAID-Induced Gastrointestinal Damage

NSAID-Induced Gastrointestinal Damage GASTROENTEROLOGY BOARD REVIEW MANUAL STATEMENT OF EDITORIAL PURPOSE The Hospital Physician Gastroenterology Board Review Manual is a study guide for fellows and practicing physicians preparing for board

More information

Drug Class Literature Scan: Proton Pump Inhibitors and Histamine-2 Receptor Antagonists

Drug Class Literature Scan: Proton Pump Inhibitors and Histamine-2 Receptor Antagonists Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Optimizing the Intragastric ph as a Supportive Therapy in Upper GI Bleeding

Optimizing the Intragastric ph as a Supportive Therapy in Upper GI Bleeding YALE JOURNAL OF BIOLOGY AND MEDICINE 69 (1996), pp. 225-23 1. Copyright C 1997. All rights reserved. Optimizing the Intragastric ph as a Supportive Therapy in Upper GI Bleeding Gorig Brunnera, Pablo Luna,

More information

Helicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W.

Helicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W. UvA-DARE (Digital Academic Repository) Helicobacter pylori infection: several studies on epidemiology, eradication and gastric epithelial cell turnover Liu, W. Link to publication Citation for published

More information

EDUCATION PRACTICE. Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? Clinical Scenario.

EDUCATION PRACTICE. Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? Clinical Scenario. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1086 1090 EDUCATION PRACTICE Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? RICHARD J. SAAD* and WILLIAM D.

More information

Clinical and Endoscopic Features of Peptic Ulcer Bleeding in Malaysia

Clinical and Endoscopic Features of Peptic Ulcer Bleeding in Malaysia Clinical and Endoscopic Features of Peptic Ulcer Bleeding in Malaysia * P Kandasami, FRCS, ** K Harjit, FRCS, *** H Hanafiah, FRCS * Department of Surgery, International Medical University, ** Department

More information

A Cost-Effective Disease Management Approach to Minimizing NSAID-Related GI Mucosal Injury

A Cost-Effective Disease Management Approach to Minimizing NSAID-Related GI Mucosal Injury A Cost-Effective Disease Management Approach to Minimizing NSAID-Related GI Mucosal Injury A. Mark Fendrick, MD Summary Nonsteroidal anti-inflammatory drugs (NSAIDs) are prescribed often in the U.S., particularly

More information

Gastritis General standpoints

Gastritis General standpoints Gastritis General standpoints Histologically documented inflammation ~60% in mucosal biopsy specimens. Heterogeneous etiology. More than 100 classification system. Classified based on time course (acute

More information

GASTROESOPHAGEAL reflux

GASTROESOPHAGEAL reflux ORIGINAL INVESTIGATION Lansoprazole Compared With Ranitidine for the Treatment of Nonerosive Gastroesophageal Reflux Disease Joel E. Richter, MD; Donald R. Campbell, MD; Peter J. Kahrilas, MD; Bidan Huang,

More information

Continuation of Low-Dose Aspirin Therapy with Either PR or PO Administration in Patients with Peptic Ulcer Bleeding

Continuation of Low-Dose Aspirin Therapy with Either PR or PO Administration in Patients with Peptic Ulcer Bleeding Continuation of Low-Dose Aspirin Therapy with Either PR or PO Administration in Patients with Peptic Ulcer Bleeding IRB Protocol Lucian Iancovici February 4, 2010 A. Study Design and Purpose Aspirin has

More information

GERD burden (GERD-en?)

GERD burden (GERD-en?) GERD burden (GERD-en?) Controversies in the Upper GI Tract Jeffrey Fox, MD, MPH UCSF Primary Care Medicine: Update 2012 Very common 25% of Americans use antacids/antisecretory meds 3X/mo $8 billion/year

More information

1. Appropriateness of Gastroscopy: Dyspepsia 1

1. Appropriateness of Gastroscopy: Dyspepsia 1 Special Topic 579 1. Appropriateness of Gastroscopy: Dyspepsia 1 F. Froehlich *, M. Bochud **, J.-J. Gonvers*, R.W. Dubois***, J.-P. Vader **, V. Wietlisbach ***, B. Burnand ** * Policlinique Médicale

More information

TEXAS VENDOR DRUG PROGRAM

TEXAS VENDOR DRUG PROGRAM 1 OF 12 Publication History o Revised March 2015; June 2013; November 2011; September 2011; September 20009; June 2009; December 2005; November 2003; October 2002. o Developed December 2001. Prepared by

More information

VUMC Multidisciplinary Surgical Critical Care

VUMC Multidisciplinary Surgical Critical Care VUMC Multidisciplinary Surgical Critical Care Gastrointestinal Stress Ulcer Prophylaxis Guideline: Background: Work by Cooke and colleagues ascribed the risk of overt bleeding to be 4.4% and clinically

More information

Helicobacter Connections. Barry Marshall

Helicobacter Connections. Barry Marshall Helicobacter Connections Barry Marshall The greatest obstacle to knowledge is not ignorance, it is the illusion of knowledge. Daniel Boorstein - Historian Peptic Ulcers Duodenal Ulcer (DU) Gastric Ulcer

More information

Effective Health Care Program

Effective Health Care Program Comparative Effectiveness Review Number 38 Effective Health Care Program Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review Executive Summary Background Osteoarthritis

More information

Peptic ulcer bleeding remains the most common cause of hospitalization

Peptic ulcer bleeding remains the most common cause of hospitalization CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:311 316 Predicting Mortality in Patients With Bleeding Peptic Ulcers After Therapeutic Endoscopy PHILIP W. Y. CHIU,* ENDERS K. W. NG,* FRANCES K. Y. CHEUNG,*

More information

All Indiana Medicaid Prescribers and Pharmacy Providers

All Indiana Medicaid Prescribers and Pharmacy Providers P R O V I D E R B U L L E T I N BT200148 NOVEMBER 28, 2001 To: All Indiana Medicaid Prescribers and Pharmacy Providers Subject: Note: The information in this bulletin regarding prior authorization payment

More information

HELICOBACTER PYLORI UPDATE

HELICOBACTER PYLORI UPDATE HELICOBACTER PYLORI UPDATE PROF. TAWHEED MOWAFY DEAN OF AZAL FACULTY OF MEDICINE INTRODUCTION (H. pylori) is recognised as the most common chronic human bacterial infection,1 affecting up to 50% of the

More information

Eugenia Lauret, Jesús Herrero, Lorena Blanco, Olegario Castaño, Maria Rodriguez, Isabel Pérez, Verónica Alvarez, Adolfo Suárez, and Luis Rodrigo

Eugenia Lauret, Jesús Herrero, Lorena Blanco, Olegario Castaño, Maria Rodriguez, Isabel Pérez, Verónica Alvarez, Adolfo Suárez, and Luis Rodrigo Gastroenterology Research and ractice Volume 2013, Article ID 584540, 5 pages http://dx.doi.org/10.1155/2013/584540 Clinical Study Epidemiological Clinical Features and Evolution of Gastroduodenal Ulcer

More information

Management of Acute Gastric Ulcer Bleeding

Management of Acute Gastric Ulcer Bleeding 16 Management of Acute Gastric Ulcer Bleeding Christo van Rensburg and Monique Marais Stellenbosch University South Africa 1. Introduction Acute gastric ulcer bleeding frequently presents as a gastrointestinal

More information

Proton Pump Inhibitors and the Treatment of GERD, Dyspepsia, NSAID-associated Peptic Ulcer Disease

Proton Pump Inhibitors and the Treatment of GERD, Dyspepsia, NSAID-associated Peptic Ulcer Disease Pharmacist Presentation Proton Pump Inhibitors and the Treatment of GERD, Dyspepsia, NSAID-associated Peptic Ulcer Disease Presenter Title Affiliation Date Disclaimer The information in this presentation

More information

Antiplatelets in cardiac patients with suspected GI bleeding

Antiplatelets in cardiac patients with suspected GI bleeding Antiplatelets in cardiac patients with suspected GI bleeding Acute GI bleeding is a common major medical emergency. In the 2007 UK-wide audit, overall mortality of patients admitted with acute GI bleeding

More information

Functional Dyspepsia. Norbert Welkovics Heine van der Walt

Functional Dyspepsia. Norbert Welkovics Heine van der Walt Norbert Welkovics Heine van der Walt Characteristics: Central abdomen Pain or discomfort Not associated with bowel movements No structural or biochemical abnormalty Definition Part of Gastroduodenal disorders

More information

Systematic Review and Meta-analysis of Adverse Events of Low-dose Aspirin and Clopidogrel in Randomized Controlled Trials

Systematic Review and Meta-analysis of Adverse Events of Low-dose Aspirin and Clopidogrel in Randomized Controlled Trials The American Journal of Medicine (2006) 119, 624-638 REVIEW Systematic Review and Meta-analysis of Adverse Events of Low-dose Aspirin and Clopidogrel in Randomized Controlled Trials Kenneth R. McQuaid,

More information

Perforated peptic ulcer

Perforated peptic ulcer Perforated peptic ulcer - Despite the widespread use of gastric anti-secretory agents and eradication therapy, the incidence of perforated peptic ulcer has changed little, age limits increase NSAIDs elderly

More information

Evidence-based medicine: data mining and pharmacoepidemiology research

Evidence-based medicine: data mining and pharmacoepidemiology research Data Mining VII: Data, Text and Web Mining and their Business Applications 307 Evidence-based medicine: data mining and pharmacoepidemiology research B. B. Little 1,2,3, R. A. Weideman 3, K. C. Kelly 3

More information

Definitive Surgical Treatment When Endoscopy Fails. Erik Peltz D.O. Resident Debate February 26 th 2007 University of Colorado Dept.

Definitive Surgical Treatment When Endoscopy Fails. Erik Peltz D.O. Resident Debate February 26 th 2007 University of Colorado Dept. Nonvariceal Gastrointestinal Hemorrhage: Definitive Surgical Treatment When Endoscopy Fails Erik Peltz D.O. Resident Debate February 26 th 2007 University of Colorado Dept. Surgery Non-Variceal Upper GI

More information

Acid Control and Healing of EE are Related. Disclosures. Perspectives on the Risk-Benefit Ratio of PPI Therapy. Risk-Benefit Ratio of PPIs

Acid Control and Healing of EE are Related. Disclosures. Perspectives on the Risk-Benefit Ratio of PPI Therapy. Risk-Benefit Ratio of PPIs Perspectives on the Risk-Benefit Ratio of PPI Therapy David C. Metz. MD Professor of Medicine Division of Gastroenterology University of Pennsylvania School of Medicine Disclosures Grant/Research Support

More information

Peptic ulcer disease 1 GIT. Dr Kawa Ahmad PhD Pharmaceutics

Peptic ulcer disease 1 GIT. Dr Kawa Ahmad PhD Pharmaceutics 51 Peptic ulcer disease Dr Kawa Ahmad PhD Pharmaceutics 1 GIT Food taken into the mouth is mixed with saliva to form a plastic mass. The salivary glands secrete about 1 L of fluid daily; this contains

More information

Helicobacter pylori eradication in patients with peptic ulcer disease: clinical consequences and financial implications

Helicobacter pylori eradication in patients with peptic ulcer disease: clinical consequences and financial implications Quarterly Journal of Medicine, 1994; 87:283-290 Helicobacter pylori eradication in patients with peptic ulcer disease: clinical consequences and financial implications K.U. POWELL 1, CD. BELL 1, G.H. BOLTON

More information

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University

Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without

More information

Endoclips vs large or small-volume epinephrine in peptic ulcer recurrent bleeding

Endoclips vs large or small-volume epinephrine in peptic ulcer recurrent bleeding Online Submissions: http://www.wjgnet.com/1007-9327office wjg@wjgnet.com doi:10.3748/wjg.v18.i18.2219 World J Gastroenterol 2012 May 14; 18(18): 2219-2224 ISSN 1007-9327 (print) ISSN 2219-2840 (online)

More information